Analysis of Predictive Factors in a Phase 3 Trial of Nab-Paclitaxel (nab-P) Plus Carboplatin (C) as First-Line Therapy for Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)
2014 ◽
Vol 90
(5)
◽
pp. S43
◽
Keyword(s):
Phase 3
◽